BlinkLab completes ten-site clinical network for pivotal FDA autism diagnostic trial
BlinkLab Limited (ASX: BB1) has finalised its BlinkLab Pivotal FDA Trial Network with the onboarding of University of Arkansas as the tenth and final clinical site. First patient testing is expected to commence later this month, marking imminent trial execution for the company’s smartphone-based autism diagnostic aid, BlinkLab Dx 1. The study will enrol a minimum of 528 children aged 2–11 years across the completed network of leading US autism clinical and research centres.
Key announcement highlights:
- 10 clinical sites now onboarded, completing the trial network
- Minimum 528 children to be enrolled in the pivotal study
- Age range: 2–11 years
- First participants expected to be enrolled and tested by end of March 2026
- Trial validates both usability and diagnostic accuracy of BlinkLab Dx 1
Network completion removes a critical execution risk and positions BlinkLab to commence the FDA 510(k) pivotal trial, a regulatory milestone that could pave the way for US market authorisation. The company has confirmed that site initiation visits are underway to verify readiness across all locations before participant recruitment begins.
When big ASX news breaks, our subscribers know first
Understanding FDA 510(k) clearance for medical device investors
FDA 510(k) clearance is a regulatory pathway for medical devices that demonstrate substantial equivalence to existing cleared devices. This pathway is typically faster and less costly than Pre-Market Approval (PMA), though it still requires clinical evidence demonstrating safety and effectiveness.
For BlinkLab, successful 510(k) clearance would authorise commercial marketing of BlinkLab Dx 1 in the United States. The regulatory pathway requires demonstrating that the device performs comparably to an existing cleared device or meets pre-agreed performance benchmarks established with the FDA.
510(k) clearance represents the gateway to US commercialisation. Investors should understand this is the primary regulatory hurdle unlocking market access for BlinkLab’s autism diagnostic technology in what is currently the world’s largest healthcare market.
Pilot study results de-risk pivotal trial with performance exceeding FDA benchmarks
BlinkLab’s October 2025 pilot study provides a strong data-driven foundation for the pivotal trial. The pilot evaluated BlinkLab Dx 1 across 485 children and demonstrated 83.7% sensitivity and 84.7% specificity versus independent gold-standard clinical diagnoses.
These results significantly exceeded the FDA-agreed performance thresholds of greater than 65% sensitivity and greater than 65% specificity established for the pivotal study. The pilot data confirmed both the robustness of the technology in real-world clinical populations and the company’s readiness to progress its pivotal 510(k) programme.
| Metric | Pilot Study Result | FDA Threshold |
|---|---|---|
| Sensitivity | 83.7% | >65% |
| Specificity | 84.7% | >65% |
| Sample Size | 485 children | N/A |
Pilot outperformance against agreed FDA benchmarks reduces regulatory risk for the pivotal study. Investors can view the pilot data as meaningful de-risking evidence that the technology meets the performance standards required for potential FDA clearance.
Strategic network of leading US autism clinical centres
The BlinkLab Pivotal FDA Trial Network now comprises ten leading autism clinical and research centres across the United States:
- Cincinnati Children’s Hospital
- Seattle Children’s Hospital
- University of Pennsylvania
- MU Thompson Center for Autism & Neurodevelopmental Disorders
- Southwest Autism Research & Resource Center
- University of Nebraska Medical Center
- Vanderbilt Kennedy Center
- Rush University Medical Center
- Drexel University
- University of Arkansas
These sites represent a geographically diverse and demographically representative sample of the US population, each with proven track records in autism research and clinical trial execution. By anchoring the pivotal trial in this elite network, BlinkLab is generating high-quality regulatory evidence whilst simultaneously building relationships with key opinion leaders and future implementation partners within major US centres of excellence.
These collaborations are expected to play a critical role in informing real-world clinical workflows for the technology, supporting guideline and payer engagement, and accelerating adoption upon FDA clearance. Elite clinical partnerships serve dual strategic purposes: regulatory credibility now and commercial adoption channels post-clearance.
Dr Henk-Jan Boele, Managing Director and CEO
“We are proud to announce the finalisation of our clinical site network for the upcoming pivotal 510(k) study. These top-tier clinical and research centres will be instrumental not only in the timely completion of our regulatory study, but also in supporting post-FDA-clearance commercialisation. Together, these key opinion leaders in the autism field will help shape the future of autism assessment and define the role that AI-enabled technologies, such as BlinkLab, will play in clinical decision-making. At BlinkLab, we are excited to begin the next phase of this journey, with participant recruitment expected to commence later this month.”
University of Arkansas brings research depth and population health focus
University of Arkansas joins the network as the final site addition. The university is recognised as a leading research institution in the United States with R1 classification (Very High Research Activity) by the Carnegie Foundation. It is the flagship campus of the broader University of Arkansas System, which includes the University of Arkansas for Medical Sciences (UAMS).
UAMS integrates the education of health professionals, clinical care, and biomedical research projects across its footprint. The centre’s research emphasis is positioned around translating research into improved care and health outcomes, with an institutional focus on population health. UAMS also maintains an Institute for Digital Health & Innovation, which aims to reduce disparities in access to healthcare through digital health technology and technology-enabled care.
The final site addition brings specific expertise in digital health translation and population health, aligning with BlinkLab’s broader market positioning of addressing long waitlists, regional inequities, and delayed care in autism diagnosis.
The next major ASX story will hit our subscribers first
Next steps and path to FDA clearance
BlinkLab and contract research organisation MCRA/IQVIA will now conduct site initiation visits to confirm readiness across all ten clinical sites. These visits verify that all locations are prepared to conduct the investigation in full compliance with the study protocol and regulatory requirements before enrolling participants.
Site initiation activities include:
- Final training of research teams across all clinical sites
- Confirmation of ethical and protocol procedures
- Verification of data collection and reporting processes
- Final operational verifications to ensure the study is conducted safely, consistently, and in accordance with regulatory standards
The pivotal study will validate both usability and diagnostic accuracy of BlinkLab Dx 1. First participants are expected to be enrolled and tested by the end of March 2026, marking the company’s transition from preparation phase to active execution toward a potential FDA clearance milestone.
A successful pivotal study and subsequent FDA 510(k) clearance would position BlinkLab Dx 1 as a first-of-its-kind AI-powered diagnostic aid that can be deployed at scale, bringing earlier and more objective autism assessments into clinics and communities to help address long waitlists, regional inequities, and delayed care and support.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment market-moving announcements hit the ASX.